DOCSLIB.ORG

Bio-Plex Pro™ Human Apolipoprotein 10-Plex Assay

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bio-Plex Pro™ Human Apolipoprotein 10-Plex Assay Metabolism Cancer Cardiovascular Disease Cytokines, Chemokines, Growth Factors Neurology Diabetes Infectious Disease ™ Inflammation Bio-Plex Pro Signal Transduction Sepsis Human Apolipoprotein 10-Plex Assay Apolipoprotein A1 / Apolipoprotein A2 / Apolipoprotein B / Apolipoprotein C1 / Apolipoprotein C3 MAGNETIC SEPARATION ENABLED Apolipoprotein D / Apolipoprotein E / Apolipoprotein H / Apolipoprotein J / C-Reactive Protein ■ All-in-one High-Performance Multiplex Assay Features premixed kit Immunoassays for Research This panel is offered in a convenient, ■ Optimized The Bio-Plex Pro Human Apolipoprotein Assay all-in-one, 10-plex kit format that includes for lot-to-lot Panel is a sensitive, magnetic bead–based magnetic capture beads, detection antibodies, reproducibility multiplex assay that allows you to accurately vial of standards, two-level controls, diluents, ■ Two-level measure nine apolipoproteins and C-reactive buffers, streptavidin-PE, flat bottom plate, and quality controls protein (CRP) in diverse matrices, including plate seals for the detection of nine human ■ Magnetic workflow serum and plasma. Multiplex capabilities apolipoproteins and CRP (Table 1). allow you to rapidly quantitate multiple ■■ Manufactured in accordance with apolipoproteins in a single microplate well GMP guidelines in just 4 hours, using only 10 µl of sample. ■■ Lot-to-lot correlation specification of Validated to rigorous analytical standards and R2 ≥ 0.9 for consistent, reproducible results designed for lot-to-lot consistency, this panel ■■ Full multiplate validation documentation is ideal for investigating biomarker profiles for each kit lot associated with the following research areas: ■■ Two-level quality controls with lot-specific ranges ■■ Cardiovascular disease ■■ Assay quick guide to get you started ■■ Inflammation right away ■■ Diabetes ■■ Fastest available assay protocols and ■■ Neurological disease a convenient all-in-one kit format ■■ Sepsis ■■ Compatible with the Bio-Plex® 200, Bio-Plex ■■ Cancer 3D Suspension Array Systems, and the Bio-Plex® MAGPIX™ Multiplex Reader ■■ Magnetic beads for simplified plate processing Table 1. Analytes detected by the Human Apolipoprotein Panel. Apo A1 Apo C3 Apo H Apo A2 Apo D Apo J Apo B Apo E CRP (C-reactive protein) Apo C1 Assay Performance Definitions The following parameters are indicative of assay performance, as shown in Table 2. Assay working range – the range of concentrations within which the assay is precise and accurate. Boundaries of the assay working range are defined by the lower limit of quantitation (LLOQ) and the upper limit of quantitation (ULOQ) Precision – the coefficient of variation (%CV) at concentrations within the assay working range Accuracy (recovery) – percentage of the observed concentration relative to the expected concentration of a known amount of analyte within the assay working range Sensitivity (limit of detection, LOD) – the concentration of analyte for which the fluorescence intensity signal is two standard deviations above the background signal Table 2. Representative performance characteristics. Assay Working Ranges, ng/ml Assay Sensitivity, ng/ml Assay Precision Analyte Alternative Bead LLOQ* ULOQ* LOD** Intra-Assay %CV Inter-Assay %CV Names Region Apolipoprotein A1 Apo A1 22 0.059 70 0.045 4 7 Apolipoprotein A2 Apo A2 26 0.032 36 0.016 6 15 Apolipoprotein B Apo B 44 0.41 360 0.22 6 12 Apolipoprotein C1 Apo C1 36 0.030 17 0.0082 3 5 Apolipoprotein C3 Apo C3 39 0.023 28 0.013 3 10 Apolipoprotein D Apo D 12 0.055 30 0.027 3 9 Apolipoprotein E Apo E 38 0.021 12 0.012 4 6 Apolipoprotein H Apo H 75 0.15 210 0.11 3 8 Apolipoprotein J Clusterin/Apo J 48 0.12 170 0.078 2 8 C-reactive protein CRP 78 0.019 11 0.0087 3 5 * LLOQ and ULOQ are the lower and upper limits of quantitation where measurements are both accurate (80–120% recovery) and precise (≤30% CV). ** LOD is the limit of detection determined by adding two standard deviations to the background median fluorescence intensity (MFI) of standard diluent and extracting the concentration from the standard curve. All values in the table represent the mean from at least three separate assay plates. Working Range The assay working range should encompass the biological range of expression in order to be useful in research. Bio-Plex Pro Assays are developed and optimized to ensure that biological samples fall within the quantifiable regions of the assay as demonstrated by comparing the standard curves of assay controls to biological samples. Apolipoprotein A1 Apolipoprotein A2 ULOQ (61.127) S1 (61.13) ULOQ (22.935) S1 (22.94) S2 (24.11) 20,000 S2 (7.67) 20,000 S3 (7.72) 10,000 10,000 S3 (2.55) Fluorescence intensity Fluorescence S4 (2.61) intensity Fluorescence S4 (0.84) LLOQ (0.032) LLOQ (0.032) 0 0 S8 (0.03) S7 (0.10) S6 (0.29) S5 (0.86) S8 S7 (0.03) S6 (0.09) S5 (0.28) 0.01 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 Concentration, ng/ml Concentration, ng/ml Apolipoprotein B Apolipoprotein C1 ULOQ (171.327) S1 (171.33) ULOQ (11.999) S1 (12.00) S2 (60.43) 20,000 20,000 S2 (4.00) 10,000 10,000 S3 (19.51) S3 (1.33) Fluorescence intensity Fluorescence Fluorescence intensity Fluorescence S4 (7.04) LLOQ (0.271) S4 (0.45) LLOQ (0.017) 0 0 S8 S7 (0.27) S6 (0.69) S5 (2.19) S8 S7 (0.02) S6 (0.05) S5 (0.15) 0.10 1.00 10.00 100.00 0.01 0.10 1.00 10.00 Concentration, ng/ml Concentration, ng/ml Apolipoprotein C3 Apolipoprotein D ULOQ (6.003) S2 (6.00) ULOQ (8.324) S2 (8.32) 20,000 20,000 S3 (2.00) 10,000 10,000 S3 (2.85) Fluorescence intensity Fluorescence Fluorescence intensity Fluorescence S4 (0.67) S4 (0.87) LLOQ (0.008) LLOQ (0.031) 0 0 S8 (0.01) S7 (0.02) S6 (0.08) S5 (0.22) S8 S7 (0.03) S6 (0.11) S5 (0.33) 0.01 0.10 1.00 10.00 0.01 0.10 1.00 10.00 Concentration, ng/ml Concentration, ng/ml Apolipoprotein E Apolipoprotein H ULOQ (7.500) ULOQ (149.128) S3 (149.13) 15,000 S1 (7.50) 15,000 10,000 S2 (50.68) 10,000 S2 (2.50) 5,000 5,000 S3 (16.30) Fluorescence intensity Fluorescence intensity Fluorescence S3 (0.82) S4 (0.29) S4 (5.75) LLOQ (0.012) LLOQ (0.200) 0 S4 (0.29) 0 S8 S7 (0.01) S6 (0.03) S5 (0.09) S8 S7 (0.20) S6 (0.64) S5 (1.78) 0.00 0.01 0.10 1.00 10.00 0.10 1.00 10.00 100.00 Concentration, ng/ml Concentration, ng/ml Apolipoprotein J CRP ULOQ (99.701) S1 (99.70) ULOQ (6.999) S1 (7.0 0) 20,000 20,000 S2 (33.71) S2 (2.33) 10,000 10,000 Fluorescence intensity Fluorescence Fluorescence intensity Fluorescence S3 (10.77) S3 (0.77) S4 (3.86) LLOQ (0.54) S4 (0.27) LLOQ (0.010) 0 0 S8 (0.05) S7 (0.13) S6 (0.40) S5 (1.240) S8 S7 (0.01) S6 (0.03) S5 (0.08) 0.01 0.10 1.00 10.00 0.00 0.01 0.10 1.00 10.00 Concentration, ng/ml Concentration, ng/ml Fig. 1. Sample detection and working range. Standard curves with assay controls and serum samples were generated per the kit protocol. Standard points were prepared by serially diluting a reconstituted standard provided in each kit to generate an eight-point standard curve. The standard calibration curves plotted with standard points ( ), samples ( ), and controls ( ) illustrate the broad working range of the assays. Shown below are representative data for serum samples from healthy control groups and patients with cancer (prostate, lung, colorectal, and ovarian). n = 63. Ordering Information Catalog # Description Catalog # Description Software 171001510 Bio-Plex Data Pro™ Software with Bio-Plex Manager™ Software, Human Apolipoprotein Assays Bio-Plex Data Pro Software (5 seats), for multi-experiment 12003081 Bio-Plex Pro Human Apolipoprotein Assay Panel, 10-plex, analysis and advanced data visualization, and Bio-Plex Manager 1 x 96-well, includes magnetic capture beads, detection antibodies, Software (5 seats), for instrument data evaluation and optimization. vial of standards, two-level controls, diluents, buffers, strepdavadin- CDs and security HASP key included PE, flat bottom plate, and plate seals for the detection of nine human 171001513 Bio-Plex Data Pro Software, (5 seats), for multi-experiment apolipoproteins and C-reactive protein analysis and advanced data visualization Wash Stations and Accessories 171STND01 Bio-Plex Manager Software, includes 1 user desktop 30034376 Bio-Plex Pro Wash Station, microplate wash station for license, for analysis of Bio-Plex data and generation of protocols, magnetic bead–based assays, includes magnetic plate carrier, does not operate the instrument waste bottle, 2 liquid bottles 171020100 Bio-Plex Handheld Magnetic Washer, includes magnetic Visit bio-rad.com/apolipoprotein for more information. washer and adjustment hex tools for use in manual wash steps for all Bio-Plex magnetic assays 171025001 Bio-Plex Pro Flat Bottom Plates, pkg of 40, 96-well plates, The Bio-Plex Suspension Array System includes fluorescently labeled for use with Bio-Plex Pro Wash Stations when using magnetic microspheres and instrumentation licensed to Bio-Rad Laboratories, Inc. bead–based assays by the Luminex Corporation. MAGPIX is a trademark of the Luminex Corporation. Bio-Rad Laboratories, Inc. Life Science Web site bio-rad.com USA 1 800 424 6723 Australia 61 2 9914 2800 Austria 43 1 877 89 01 177 Belgium 32 (0)3 710 53 00 Brazil 55 11 3065 7550 Canada 1 905 364 3435 China 86 21 6169 8500 Czech Republic 420 241 430 532 Denmark 45 44 52 10 00 Finland 358 09 804 22 00 Group France 33 01 47 95 69 65 Germany 49 89 31 884 0 Hong Kong 852 2789 3300 Hungary 36 1 459 6100 India 91 124 4029300 Israel 972 03 963 6050 Italy 39 02 216091 Japan 81 3 6361 7000 Korea 82 2 3473 4460 Mexico 52 555 488 7670 The Netherlands 31 (0)318 540 666 New Zealand 64 9 415 2280 Norway 47 23 38 41 30 Poland 48 22 331 99 99 Portugal 351 21 472 7700 Russia 7 495 721 14 04 Singapore 65 6415 3188 South Africa 27 (0) 861 246 723 Spain 34 91 590 5200 Sweden 46 08 555 12700 Switzerland 41 026 674 55 05 Taiwan 886 2 2578 7189 Thailand 66 2 651 8311 United Arab Emirates 971 4 8187300 United Kingdom 44 020 8328 2000 Bulletin 7018 Ver A US/EG 17-0765 1017 Sig 1216.
Load more

Recommended publications
  • The Expression of the Human Apolipoprotein Genes and Their Regulation by Ppars
    CORE Metadata, citation and similar papers at core.ac.uk Provided by UEF Electronic Publications The expression of the human apolipoprotein genes and their regulation by PPARs Juuso Uski M.Sc. Thesis Biochemistry Department of Biosciences University of Kuopio June 2008 Abstract The expression of the human apolipoprotein genes and their regulation by PPARs. UNIVERSITY OF KUOPIO, the Faculty of Natural and Environmental Sciences, Curriculum of Biochemistry USKI Juuso Oskari Thesis for Master of Science degree Supervisors Prof. Carsten Carlberg, Ph.D. Merja Heinäniemi, Ph.D. June 2008 Keywords: nuclear receptors; peroxisome proliferator-activated receptor; PPAR response element; apolipoprotein; lipid metabolism; high density lipoprotein; low density lipoprotein. Lipids are any fat-soluble, naturally-occurring molecules and one of their main biological functions is energy storage. Lipoproteins carry hydrophobic lipids in the water and salt-based blood environment for processing and energy supply in liver and other organs. In this study, the genomic area around the apolipoprotein genes was scanned in silico for PPAR response elements (PPREs) using the in vitro data-based computer program. Several new putative REs were found in surroundings of multiple lipoprotein genes. The responsiveness of those apolipoprotein genes to the PPAR ligands GW501516, rosiglitazone and GW7647 in the HepG2, HEK293 and THP-1 cell lines were tested with real-time PCR. The APOA1, APOA2, APOB, APOD, APOE, APOF, APOL1, APOL3, APOL5 and APOL6 genes were found to be regulated by PPARs in direct or secondary manners. Those results provide new insights in the understanding of lipid metabolism and so many lifestyle diseases like atherosclerosis, type 2 diabetes, heart disease and stroke.
    [Show full text]
  • Clusterin and LRP2 Are Critical Components of the Hypothalamic Feeding Regulatory Pathway
    ARTICLE Received 21 Sep 2012 | Accepted 16 Apr 2013 | Published 14 May 2013 DOI: 10.1038/ncomms2896 Clusterin and LRP2 are critical components of the hypothalamic feeding regulatory pathway So Young Gil1, Byung-Soo Youn2, Kyunghee Byun3,4, Hu Huang5, Churl Namkoong1, Pil-Geum Jang1, Joo-Yong Lee1, Young-Hwan Jo6, Gil Myoung Kang1, Hyun-Kyong Kim1, Mi-Seon Shin7, Claus U. Pietrzik8, Bonghee Lee3,4, Young-Bum Kim3,5 & Min-Seon Kim1,7 Hypothalamic feeding circuits are essential for the maintenance of energy balance. There have been intensive efforts to discover new biological molecules involved in these pathways. Here we report that central administration of clusterin, also called apolipoprotein J, causes anorexia, weight loss and activation of hypothalamic signal transduction-activated transcript-3 in mice. In contrast, inhibition of hypothalamic clusterin action results in increased food intake and body weight, leading to adiposity. These effects are likely mediated through the mutual actions of the low-density lipoprotein receptor-related protein-2, a potential receptor for clusterin, and the long-form leptin receptor. In response to clusterin, the low-density lipoprotein receptor-related protein-2 binding to long-form leptin receptor is greatly enhanced in cultured neuronal cells. Furthermore, long-form leptin receptor deficiency or hypothalamic low-density lipoprotein receptor-related protein-2 suppression in mice leads to impaired hypothalamic clusterin signalling and actions. Our study identifies the hypotha- lamic clusterin–low-density lipoprotein receptor-related protein-2 axis as a novel anorexigenic signalling pathway that is tightly coupled with long-form leptin receptor-mediated signalling. 1 Asan Institute for Life Science, University of Ulsan College of Medicine, Seoul 138-736, Korea.
    [Show full text]
  • Brain-Specific Lipoprotein Receptors Interact with Astrocyte Derived
    ARTICLE https://doi.org/10.1038/s41467-021-22751-7 OPEN Brain-specific lipoprotein receptors interact with astrocyte derived apolipoprotein and mediate neuron-glia lipid shuttling Jun Yin1, Emma Spillman1,5, Ethan S. Cheng1, Jacob Short 1, Yang Chen1, Jingce Lei1, Mary Gibbs1, Justin S. Rosenthal1, Chengyu Sheng 1,6, Yuki X. Chen2,3, Kelly Veerasammy2,3, Tenzin Choetso2,3, ✉ Rinat Abzalimov2, Bei Wang 4, Chun Han 4,YeHe2 & Quan Yuan 1 1234567890():,; Lipid shuttling between neurons and glia contributes to the development, function, and stress responses of the nervous system. To understand how a neuron acquires its lipid supply from specific lipoproteins and their receptors, we perform combined genetic, transcriptome, and biochemical analyses in the developing Drosophila larval brain. Here we report, the astrocyte- derived secreted lipocalin Glial Lazarillo (GLaz), a homolog of human Apolipoprotein D (APOD), and its neuronal receptor, the brain-specific short isoforms of Drosophila lipophorin receptor 1 (LpR1-short), cooperatively mediate neuron-glia lipid shuttling and support den- drite morphogenesis. The isoform specificity of LpR1 defines its distribution, binding partners, and ability to support proper dendrite growth and synaptic connectivity. By demonstrating physical and functional interactions between GLaz/APOD and LpR1, we elucidate molecular pathways mediating lipid trafficking in the fly brain, and provide in vivo evidence indicating isoform-specific expression of lipoprotein receptors as a key mechanism for regulating cell- type specific lipid recruitment. 1 Dendrite Morphogenesis and Plasticity Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. 2 The City University of New York, Graduate Center-Advanced Science Research Center, New York, NY, USA.
    [Show full text]
  • Convergence of Genes Implicated in Alzheimer's Disease on the Cerebral
    Neurochemistry International 50 (2007) 12–38 www.elsevier.com/locate/neuint Review Convergence of genes implicated in Alzheimer’s disease on the cerebral cholesterol shuttle: APP, cholesterol, lipoproteins, and atherosclerosis C.J. Carter 176 Downs Road, Hastings, East Sussex TN34 2DZ, UK Received 5 April 2006; received in revised form 30 June 2006; accepted 11 July 2006 Available online 12 September 2006 Abstract Polymorphic genes associated with Alzheimer’s disease (see www.polygenicpathways.co.uk) delineate a clearly defined pathway related to cerebral and peripheral cholesterol and lipoprotein homoeostasis. They include all of the key components of a glia/neurone cholesterol shuttle including cholesterol binding lipoproteins APOA1, APOA4, APOC1, APOC2, APOC3, APOD, APOE and LPA, cholesterol transporters ABCA1, ABCA2, lipoprotein receptors LDLR, LRP1, LRP8 and VLDLR, and the cholesterol metabolising enzymes CYP46A1 and CH25H, whose oxysterol products activate the liver X receptor NR1H2 and are metabolised to esters by SOAT1. LIPA metabolises cholesterol esters, which are transported by the cholesteryl ester transport protein CETP. The transcription factor SREBF1 controls the expression of most enzymes of cholesterol synthesis. APP is involved in this shuttle as it metabolises cholesterol to 7-betahydroxycholesterol, a substrate of SOAT1 and HSD11B1, binds to APOE and is tethered to LRP1 via APPB1, APBB2 and APBB3 at the cytoplasmic domain and via LRPAP1 at the extracellular domain. APP cleavage products are also able to prevent cholesterol binding to APOE. BACE cleaves both APP and LRP1. Gamma-secretase (PSEN1, PSEN2, NCSTN) cleaves LRP1 and LRP8 as well as APP and their degradation products control transcription factor TFCP2, which regulates thymidylate synthase (TS) and GSK3B expression.
    [Show full text]
  • Effects of Apolipoprotein E on Olfactory Neuron Plasticity in Mice
    Eastern Illinois University The Keep Masters Theses Student Theses & Publications 2000 Effects Of Apolipoprotein E On Olfactory Neuron Plasticity In Mice Rafia Nisar Eastern Illinois University This research is a product of the graduate program in Biological Sciences at Eastern Illinois University. Find out more about the program. Recommended Citation Nisar, Rafia, "Effects Of Apolipoprotein E On Olfactory Neuron Plasticity In Mice" (2000). Masters Theses. 1479. https://thekeep.eiu.edu/theses/1479 This is brought to you for free and open access by the Student Theses & Publications at The Keep. It has been accepted for inclusion in Masters Theses by an authorized administrator of The Keep. For more information, please contact [email protected]. THESIS REPRODUCTION CERTIFICATE TO: Graduate Degree Candidates (who have written formal theses) SUBJECT: Permission to Reproduce Theses The University Library is receiving a number of request from other institutions asking permission to reproduce dissertations for inclusion in their library holdings. Although no copyright laws are involved, we feel that professional courtesy demands that permission be obtained from the author before we allow these to be copied. PLEASE SIGN ONE OF THE FOLLOWING STATEMENTS: Booth Library of Eastern Illinois University has my permission to lend my thesis to a reputable college or university or the purpose of copying it for inclusion in that institution's library or research holdings. I Date I respectfully request Booth Library of Eastern Illinois University NOT allow
    [Show full text]
  • Apolipoprotein a II (APOA2) (NM 001643) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RC202723 Apolipoprotein A II (APOA2) (NM_001643) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: Apolipoprotein A II (APOA2) (NM_001643) Human Tagged ORF Clone Tag: Myc-DDK Symbol: APOA2 Synonyms: Apo-AII; ApoA-II; apoAII Vector: pCMV6-Entry (PS100001) E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin ORF Nucleotide >RC202723 ORF sequence Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGAAGCTGCTCGCAGCAACTGTGCTACTCCTCACCATCTGCAGCCTTGAAGGAGCTTTGGTTCGGAGAC AGGCAAAGGAGCCATGTGTGGAGAGCCTGGTTTCTCAGTACTTCCAGACCGTGACTGACTATGGCAAGGA CCTGATGGAGAAGGTCAAGAGCCCAGAGCTTCAGGCCGAGGCCAAGTCTTACTTTGAAAAGTCAAAGGAG CAGCTGACACCCCTGATCAAGAAGGCTGGAACGGAACTGGTTAACTTCTTGAGCTATTTCGTGGAACTTG GAACACAGCCTGCCACCCAG ACGCGTACGCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATGATATCCTGGATT ACAAGGATGACGACGATAAGGTTTAA Protein Sequence: >RC202723 protein sequence Red=Cloning site Green=Tags(s) MKLLAATVLLLTICSLEGALVRRQAKEPCVESLVSQYFQTVTDYGKDLMEKVKSPELQAEAKSYFEKSKE QLTPLIKKAGTELVNFLSYFVELGTQPATQ TRTRPLEQKLISEEDLAANDILDYKDDDDKV Chromatograms: https://cdn.origene.com/chromatograms/mk6050_c11.zip Restriction Sites: SgfI-MluI This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies,
    [Show full text]
  • Hormonal Regulation of Serum Lp (A) Levels
    Hormonal Regulation of Serum Lp (a) Levels Opposite Effects after Estrogen Treatment and Orchidectomy in Males with Prostatic Carcinoma Peter Henriksson, Bo Angelin, and Lars Berglund Metabolism Unit, Departments ofMedicine and Clinical Chemistry, Karolinska Institutet at Huddinge University Hospital, S-141 86 Huddinge, Sweden Abstract quently increased (12, 25-27). The role of the LDL receptor in the clearance of Lp (a) is still debated, however. Thus, no re- Serum concentrations of lipoprotein (a) [Lp (a)j were deter- duction in Lp (a) levels has been observed during treatment mined in two groups of elderly males suffering from prostatic with drugs known to stimulate the elimination of LDL from carcinoma, who were randomized to treatment with estrogen (n plasma via induction of LDL receptors, such as cholestyramine = 15) or orchidectomy (n = 16). Estrogen was given as oral and cholesterol synthesis inhibitors (12, 28-30). On the other ethinylestradiol, 150 ,ug daily, combined with intramuscular hand, overexpression ofthe human LDL receptor in transgenic polyestradiol phosphate, 80 mg/mo. The baseline levels were mice clearly increases the plasma clearance of Lp (a) (31). The similar in both groups, but 6 mo after initiation of therapy, only hypolipidemic agent reported to lower Lp (a) levels is serum Lp (a) levels were decreased 50% in the estrogen- nicotinic acid (32), particularly when combined with neomy- treated group (P < 0.001) in contrast to a 20% increase (P cin (33). This has been taken as evidence for the concept that < 0.01) in the orchidectomized group. Concomitantly, LDL cho- changes in Lp (a) synthesis rate may be more important than lesterol decreased by 30% and HDL cholesterol increased by changes in clearance in the determination of serum Lp (a) lev- almost 60% in the estrogen-treated patients.
    [Show full text]
  • Sequence Variation in the Apoa2 Gene and Its Relationship with Plasma Hdl-Cholesterol Levels
    SEQUENCE VARIATION IN THE APOA2 GENE AND ITS RELATIONSHIP WITH PLASMA HDL-CHOLESTEROL LEVELS by Sally Marie Hollister B.S., University of Michigan, 2005 Submitted to the Graduate Faculty of The Department of Human Genetics, Genetic Counseling Graduate School of Public Health in partial fulfillment of the requirements for the degree of Master of Science University of Pittsburgh 2008 UNIVERSITY OF PITTSBURGH Graduate School of Public Health This thesis was presented by Sally Marie Hollister It was defended on April 9, 2008 and approved by Thesis Advisor: M. Ilyas Kamboh, Ph.D. Professor and Acting Chair Department of Human Genetics Graduate School of Public Health University of Pittsburgh Committee Member: F. Yeşim Demirci, M.D. Research Assistant Professor Department of Human Genetics Graduate School of Public Health University of Pittsburgh Committee Member: David N. Finegold, M.D. Professor Department of Pediatrics and Human Genetics School of Medicine and Graduate School of Public Health University of Pittsburgh ii Copyright © by Sally Marie Hollister 2008 iii M. Ilyas Kamboh, Ph.D. SEQUENCE VARIATION IN THE APOA2 GENE AND ITS RELATIONSHIP WITH PLASMA HDL-CHOLESTEROL LEVELS Sally Marie Hollister, M.S. University of Pittsburgh, 2008 Coronary heart disease (CHD) is a major public health concern, affecting almost 16 million people in the U.S. and leading to 452,300 deaths in 2004 alone. Low levels of high density lipoprotein (HDL) cholesterol have been shown to increase the risk for cardiovascular disease (CVD). The role of genetics in affecting total cholesterol, HDL-cholesterol, and triglycerides levels is significant, with heritability estimates exceeding 50%. Recent studies have identified major loci associated with HDL-cholesterol through genome-wide association studies, which investigated influences of common variants on common traits.
    [Show full text]
  • Variations in the Promoter Region of the Apolipoprotein A-1 Gene Influence Plasma Lipoprotein(A)
    0031-3998/01/4904-0514 PEDIATRIC RESEARCH Vol. 49, No. 4, 2001 Copyright © 2001 International Pediatric Research Foundation, Inc. Printed in U.S.A. Variations in the Promoter Region of the Apolipoprotein A-1 Gene Influence Plasma Lipoprotein(a) Levels in Asian Indian Neonates from Singapore CHEW-KIAT HENG, POH-SIM LOW, AND NILMANI SAHA Department of Paediatrics, National University of Singapore, Singapore 119074 ABSTRACT We studied the influence of two DNA polymorphisms (Ϫ75 levels were also significantly different between composite geno- bp G/A and ϩ83 bp C/T) in the promoter region of the apoli- types in the order GG/TT Ͼ GA/CT Ͼ GG/CT Ͼ GA/CC Ͼ poprotein A-1 (apoA1) gene on cord plasma level of lipopro- GG/CC Ͼ AA/CC. The effects of the two polymorphisms seem to tein(a) [Lp(a)] in 1076 newborns of both genders from the three be additive as the composite genotypes were able to explain 14% major ethnic groups in Singapore—Chinese, Malays, and Asian of the Lp(a) variance, equivalent to the sum of the two constit- Indians. The frequency of the A allele at Ϫ75 bp in the Indians uent sites. Our results showed that there is significant ethnic- and was significantly lower than the Chinese and Malays. There was gender-specific influence of the apoA1 gene on plasma Lp(a) no linkage disequilibrium between the two sites studied. Both levels at birth that is inherent and independent of known gene- polymorphic sites were not significantly associated with any lipid environment interactions. (Pediatr Res 49: 514–518, 2001) factors except for Lp(a) levels in the Asian Indians.
    [Show full text]
  • Cerebral Apolipoprotein D Exits the Brain and Accumulates in Peripheral Tissues
    International Journal of Molecular Sciences Article Cerebral Apolipoprotein D Exits the Brain and Accumulates in Peripheral Tissues Frederik Desmarais 1,2,† , Vincent Hervé 2,3,† , Karl F. Bergeron 1 , Gaétan Ravaut 1 , Morgane Perrotte 3, Guillaume Fyfe-Desmarais 1,2, Eric Rassart 2, Charles Ramassamy 3,* and Catherine Mounier 1,* 1 Laboratoire du Métabolisme Moléculaire des Lipides, Centre de Recherches CERMO-FC, Département des Sciences Biologiques, Université du Québec à Montréal (UQAM), 141 av. du Président-Kennedy, Montréal, QC H2X 1Y4, Canada; [email protected] (F.D.); [email protected] (K.F.B.); [email protected] (G.R.); [email protected] (G.F.-D.) 2 Laboratoire de Biologie Moléculaire, Département des Sciences Biologiques, Université du Québec à Montréal (UQAM), 141 av. du Président-Kennedy, Montréal, QC H2X 1Y4, Canada; [email protected] (V.H.); [email protected] (E.R.) 3 Centre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique (INRS), 531 boul. des Prairies, Laval, QC H7V 1B7, Canada; [email protected] * Correspondence: [email protected] (C.R.); [email protected] (C.M.) † These authors contributed equally to this work. Abstract: Apolipoprotein D (ApoD) is a secreted lipocalin associated with neuroprotection and lipid metabolism. In rodent, the bulk of its expression occurs in the central nervous system. Despite this, ApoD has profound effects in peripheral tissues, indicating that neural ApoD may reach peripheral organs. We endeavor to determine if cerebral ApoD can reach the circulation and accumulate in Citation: Desmarais, F.; Hervé, V.; peripheral tissues.
    [Show full text]
  • Selective Reduction of Hydroperoxyeicosatetraenoic Acids
    University of Wollongong Research Online Faculty of Science - Papers (Archive) Faculty of Science, Medicine and Health 1-1-2012 Selective reduction of hydroperoxyeicosatetraenoic acids to their hydroxy derivatives by apolipoprotein D: implications for lipid antioxidant activity and Alzheimer's disease Surabhi Bhatia Neuroscience Research Australia Bianca Knoch University of Wollongong Jenny Wong University of Wollongong, [email protected] Woojin Scott Kim Prince of Wales Hopsital Paul Else University of Wollongong, [email protected] See next page for additional authors Follow this and additional works at: https://ro.uow.edu.au/scipapers Part of the Life Sciences Commons, Physical Sciences and Mathematics Commons, and the Social and Behavioral Sciences Commons Recommended Citation Bhatia, Surabhi; Knoch, Bianca; Wong, Jenny; Kim, Woojin Scott; Else, Paul; Oakley, Aaron J.; and Garner, Brett: Selective reduction of hydroperoxyeicosatetraenoic acids to their hydroxy derivatives by apolipoprotein D: implications for lipid antioxidant activity and Alzheimer's disease 2012, 713-721. https://ro.uow.edu.au/scipapers/4729 Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: [email protected] Selective reduction of hydroperoxyeicosatetraenoic acids to their hydroxy derivatives by apolipoprotein D: implications for lipid antioxidant activity and Alzheimer's disease Abstract ApoD (apolipoprotein D) is up-regulated in AD (Alzheimer's disease) and upon oxidative stress. ApoD inhibits brain lipid peroxidation in vivo, but the mechanism is unknown. Specific methionine esiduesr may inhibit lipid peroxidation by reducing radical-propagating L-OOHs (lipid hydroperoxides) to non-reactive hydroxides via a reaction that generates MetSO (methionine sulfoxide).
    [Show full text]
  • APOC2 Accelerates Colorectal Cancer Progression Via Modulating Lipid Metabolism and Transcriptional Activity of PHF8 (35280 Characters)
    bioRxiv preprint doi: https://doi.org/10.1101/680967; this version posted June 24, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license. APOC2 accelerates colorectal cancer progression via modulating lipid metabolism and transcriptional activity of PHF8 (35280 characters) Jian Chen1†, Chao Xiao2†, Yupeng Wang3†, Guohe Song3, Xiaoliang Wang4, Xueni Liu4, Jiayi Chen4, Huijun Lu5, Jing Kuai6, Xuebin Qin7, Weiping Guo8*, Huamei Tang9*, Zhihai Peng9* 1 Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China 2 Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China 3 Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China 4 Department of General Surgery, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China 5 Department of Pathology, Guigang City People's Hospital, Guigang, China 6 Department of General Surgery, Weifang People’s Hospital, Weifang, China 7 Department of Neuroscience, School of Medicine, Temple University, Philadelphia, USA 8 Department of gastrointestinal surgery, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China 9 Department of General Surgery, Xiamen University affiliated Xiang An Hospital, Xiamen, China † These authors contributed equally to this work. * Corresponding authors: Zhihai Peng, M.D. & Ph. D. Department of General Surgery, Xiamen University affiliated Xiang An Hospital. 2000 Xiang An East Road, Xiamen 361100, China. Email: [email protected] Huamei Tang, M.D., & Ph.
    [Show full text]